Search results for " Drug Therapy"

showing 5 items of 95 documents

SGLT2 inhibitors in T2D and associated comorbidities - differentiating within the class

2019

Abstract Background For patients with type 2 diabetes (T2D), cardiovascular disease (CVD) is the single most common cause of mortality. In 2008 and 2012, the Federal Drug Administration (FDA) and the European Medicines Agency (EMA) respectively mandated cardiovascular outcomes trials (CVOTs) on all new anti-diabetic agents, as prospective trials statistically powered to rule out excess cardiovascular risk in patients with T2D. Unexpectedly, some of these CVOTs have demonstrated not only cardiovascular safety, but also cardioprotective effects, as was first shown for the SGLT2 inhibitor empagliflozin in EMPA-REG OUTCOME. Expert opinion To debate newly available CVOT data and to put them into…

medicine.medical_specialtyDiabetes mellitus type 2 ; drug therapy ; Cardiovascular diseases ; drug therapy ; Canagliflozin ; therapeutic use ; Benzhydryl compounds ; therapeutic use ; Glucosides ; therapeutic use ; Sodium-Glucose Transporter 2 Inhibitors ; therapeutic useEndocrinology Diabetes and MetabolismEmpagliflozin610 Medicine & health030209 endocrinology & metabolismContext (language use)ComorbidityType 2 diabetesDiseaseCanagliflozin ; Cardiovascular disease ; Dapagliflozin ; Empagliflozin ; SGLT2 inhibitor ; Type 2 diabetes.lcsh:Diseases of the endocrine glands. Clinical endocrinology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDiabetes mellitusCorrespondenceEmpagliflozinHumansMedicine030212 general & internal medicineCanagliflozinDapagliflozinIntensive care medicineSodium-Glucose Transporter 2 InhibitorsCanagliflozinlcsh:RC648-665business.industryIncidence616.379-008.64 [udc]Type 2 diabetesSGLT2 inhibitorGeneral MedicineDapagliflozinCardiovascular diseasePrognosismedicine.disease3. Good healthEastern europeanDiabetes Mellitus Type 2chemistryCardiovascular Diseasesbusinessmedicine.drug
researchProduct

Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society

2011

Three years after the introduction of natalizumab (NA) therapy for the second line treatment of relapsing-remitting multiple sclerosis (MS), Italian MS centers critically reviewed the scientific literature and their own clinical experience. Natalizumab was shown to be highly efficacious in the treatment of MS. However, the risk of progressive multifocal leukoencephalopathy was confirmed and defined better. This article summarizes the MS-SIN Study Group recommendations on the use of NA in MS, with particular reference to the appropriate selection and monitoring of patients as well as to the management of adverse events.

medicine.medical_specialtyPediatricspml; iris; multiple sclerosis; natalizumabMultiple SclerosisNeurologypmlMEDLINEProgressive MultifocalDermatologyRelapsing-RemittingAntibodies Monoclonal HumanizedAntibodiesLeukoencephalopathyMultiple Sclerosis Relapsing-RemittingNatalizumabLeukoencephalopathyMonoclonalmedicineHumansAdverse effectAntibodies; Monoclonal; Humanized Antibodies; therapeutic use Humans Leukoencephalopathy; Progressive Multifocal; chemically induced Multiple Sclerosis; Relapsing-Remitting; drug therapyHumanizedMultiple sclerosis Natalizumab PML IRISirisbusiness.industryNatalizumabProgressive multifocal leukoencephalopathyMultiple sclerosisLeukoencephalopathy Progressive MultifocalAntibodies MonoclonalGeneral Medicinemedicine.diseasedrug therapyPsychiatry and Mental healththerapeutic usechemically inducednatalizumab multiple sclerosis treatment guidelinesPhysical therapySettore MED/26 - NeurologiaNeurology (clinical)Neurosurgerybusinessmedicine.drug
researchProduct

The evaluation of psychiatric drug therapy on oral lichen planus patients with psychiatric disorders

2008

Objectives: Current treatments of oral lichen planus are palliative, not curative. Because psychiatric disorders significantly influence the development and severity of oral lichen planus, the use of psychiatric drug therapy may be an adjunct in treatment. The purpose of this study was to determine the efficacy of drug therapy of psychiatric disorders in oral lichen planus. Study design: Our controlled clinical study consisted of forty-six patients with oral lichen planus and psychiatric disorders who were randomly divided into two groups. Both groups were given topical corticosteroids and the study group received additional psychiatric drug therapy. Patients were monitored for a period of …

medicine.medical_specialtyPsychiatric drug therapylaw.inventionClinical studyLesionPharmacotherapyRandomized controlled trialstomatognathic systemlawmedicineHumansSingle-Blind MethodPsychiatryGeneral Dentistrybusiness.industryMental DisordersTreatment methodmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Response to treatmentstomatognathic diseasesOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASSurgeryOral lichen planusmedicine.symptombusinessLichen Planus Oral
researchProduct

Serenoa repens, lycopene and selenium versus tamsulosin for the treatment of LUTS/BPH. An Italian multicenter double-blinded randomized study between…

2014

serenoa repensMaleProstatic HyperplasiaAntioxidantsSettore MED/24 - UrologiaSeleniumDouble-Blind MethodDrug TherapyLower Urinary Tract SymptomsSerenoa80 and overHumansBPH; LUTS; lycopene; phytotherapy; selenium; serenoa repens; tamsulosin; Aged; Aged 80 and over; Antioxidants; Carotenoids; Double-Blind Method; Drug Therapy Combination; Humans; Italy; Lower Urinary Tract Symptoms; Male; Middle Aged; Phytotherapy; Prostatic Hyperplasia; Quality of Life; Selenium; Serenoa; Sulfonamides; Treatment Outcome; Urodynamics; Urological AgentsAgedSulfonamidesLUTSphytotherapyMiddle AgedlycopeneCarotenoidsBPH LUTS lycopene phytotherapy selenium serenoa repens tamsulosinUrodynamicsTreatment OutcomeItalyBPHtamsulosinCombinationQuality of LifeUrological Agentsserenoa repens; lycopene; selenium; tamsulosin; LUTS; BPH; phytotherapy
researchProduct

Absence of Adverse Effects of Tiotropium/Olodaterol Compared with the Monocomponents on Long-Term Heart Rate and Blood Pressure in Patients with Mode…

2020

Stefan Andreas,1,2 Lorcan McGarvey,3 Ulrich Bothner,4 Matthias Trampisch,4 Alberto de la Hoz,4 Matjaz Fležar,5 Roland Buhl,6 Peter Alter7 1Department of Cardiology and Pneumology, University Medical Center Göttingen, Göttingen, Germany; 2LungClinic Immenhausen, Immenhausen, Germany, Member of the German Center for Lung Research (DZL); 3Queen’s University Belfast, Belfast, UK; 4Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany; 5Klinika Golnik, Golnik, Slovenia; 6Pulmonary Department, Johannes Gutenberg University Mainz, Mainz, Germany; 7Department of Medicine, Pulmonary and Critical Care Medicine, Philipps University of Marburg (UMR); Member o…

srčna frekvencamedicine.medical_specialtymedicine.drug_classDiastoleBlood PressureInternational Journal of Chronic Obstructive Pulmonary Diseasechronic obstructive -- drug therapychronic obstructive pulmonary disease03 medical and health scienceschemistry.chemical_compoundPulmonary Disease Chronic Obstructive0302 clinical medicinetiotropiumDouble-Blind MethodHeart RateInternal medicineBronchodilatorForced Expiratory VolumeHeart ratePost-hoc analysisheart ratemedicineHumans030212 general & internal medicineTiotropium BromideAdverse effectudc:616.2pulmonary diseasekrvni tlaktOriginal ResearchtiotropijCOPDbusiness.industryolodaterolkronična obstruktivna pljučna bolezen -- terapija z zdraviliOlodaterolblood pressureGeneral Medicinemedicine.diseasehumanities3. Good healthBenzoxazinesBronchodilator AgentsBlood pressureTreatment Outcome030228 respiratory systemchemistryCardiologybusinessInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct